Vir Biotechnology (NASDAQ: VIR) ex-officer files notice for potential $245K stock sale

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) is the issuer of common stock that a former officer, Jason V. O'Byrne, has notified under Rule 144 may be sold. The notice covers up to 25,000 shares of common stock, to be sold through Fidelity Brokerage Services LLC on or after 08/21/2026, in connection with a stock option exercise.

Key Figures

Shares covered by Rule 144 notice: 25,000 shares of common stock Aggregate market value: $245,297.00 Planned transaction date: 08/21/2026 +2 more

5 metrics

Shares covered by Rule 144 notice 25,000 shares of common stock Maximum number of Vir Biotechnology, Inc. shares indicated for potential sale

Aggregate market value $245,297.00 Aggregate market value listed for the 25,000 shares of common stock

Planned transaction date 08/21/2026 Date associated with the stock option exercise and potential sale

Form 144 related person Jason V. O'Byrne Former officer on whose account the securities may be sold

Broker Fidelity Brokerage Services LLC Broker designated for the potential sale of the shares

Key Terms

Rule 144, Stock Option Exercise, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 08/21/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

attorney-in-fact regulatory

"as a duly authorized representative ... as attorney-in-fact for Jason V. O'Byrne"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What does the Form 144 filing related to VIR disclose?

It discloses that former officer Jason V. O'Byrne has filed a notice under Rule 144 for the potential sale of up to 25,000 shares of Vir Biotechnology, Inc. common stock, to be sold through Fidelity Brokerage Services LLC in connection with a stock option exercise.

How many VIR shares are covered by this Form 144 notice?

The notice covers up to 25,000 shares of Vir Biotechnology, Inc. common stock. These shares are associated with a stock option exercise and are the maximum amount indicated for potential sale under this Rule 144 filing.

What is the aggregate market value of the VIR shares in this Form 144?

The Form 144 lists an aggregate market value of approximately $245,297.00 for the 25,000 shares of Vir Biotechnology, Inc. common stock that are the subject of the notice.

Who is the person planning to sell VIR shares under this Form 144?

The person is Jason V. O'Byrne, identified as a former officer of Vir Biotechnology, Inc.. The Form 144 is signed by Fidelity Brokerage Services LLC as attorney-in-fact on his behalf.

On what exchange are the VIR shares in this Form 144 listed?

The common stock referenced in the Form 144 filing for Vir Biotechnology, Inc. is indicated as being traded on the NASDAQ market.

What is the transaction type mentioned for the VIR shares in this Form 144?

The Form 144 states that the 25,000 shares of Vir Biotechnology, Inc. common stock are related to a Stock Option Exercise, with the transaction method listed as Cash on 08/21/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 03:24 PM Accepted by SEC EDGAR 08/21/2026 - 03:24 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001871145
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vir Biotechnology, Inc.
SEC File Number	001-39083
Address of Issuer	1800 OWENS STREET SUITE 900 SAN FRANCISCO CALIFORNIA 94158
Phone	415-906-4324
Name of Person for Whose Account the Securities are To Be Sold	O'Byrne Jason
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Former Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	25000	245297.00	169215958	08/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/21/2026	Stock Option Exercise	Issuer			25000	08/21/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/21/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jason V. O'Byrne
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)